Today we announced that the complete study results from the CAHtalyst™ Phase 3 Adult and Pediatric studies have been published in The New England Journal of Medicine (NEJM Group). In addition to being published in the journal, the data were also shared at Endocrine Society 2024. #ENDO2024 https://lnkd.in/g5pRJcnc https://lnkd.in/g_8mvpe5
This is great news for such an underserved patient community! 👏👏👏 Amazing work!
Exciting times for CAH-ers!! 🙌🏼🙌🏼
Well done! Congratulations and all the best.
Exciting news for Neurocrine and, more importantly, for CAH patients.
Well done Vivian and team! Congratulations!!!
Well done!
Exciting times!
Impressive!
Great news!
Board-Certified Pediatric Endocrinologist | Physician | Advocate for Children's Health | Assistant Professor of Pediatrics
3moGreat hope for patients with CAH. And exciting news for us endocrinologists! Managing CAH can be so challenging. Crinecerfont is an oral, selective corticotropin-releasing factor type 1 receptor antagonist being investigated to help reduce and control excess adrenal androgens through a steroid-independent mechanism.